Oracle Investment Management Inc Adaptimmune Therapeutics PLC Transaction History

Oracle Investment Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$3.63 - $6.06 $192,103 - $320,701	-52,921 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$3.76 - $14.16 $3.18 Million - $12 Million	-844,573 Reduced 94.1%	52,921 $304,000
Q3 2018 Nov 14, 2018	SELL	$8.27 - $13.56 $4.1 Million - $6.73 Million	-496,249 Reduced 35.61%	897,494 $12.2 Million
Q2 2018 Aug 14, 2018	BUY	$10.42 - $13.74 $663,472 - $874,867	63,673 Added 4.79%	1,393,743 $16.5 Million
Q1 2018 May 15, 2018	BUY	$7.1 - $11.56 $2.11 Million - $3.44 Million	297,349 Added 28.79%	1,330,070 $14.9 Million
Q4 2017 Feb 14, 2018	BUY	$6.68 - $8.74 $2.21 Million - $2.89 Million	330,860 Added 47.14%	1,032,721 $6.9 Million
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $3.46 Million - $6.27 Million	701,861	701,861 $5.75 Million

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $94.8M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Oracle Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Oracle Investment Management Inc with notifications on news.